Kidney Cancer is committed to the highest ethical standards and best practices in publishing and follows the code of conduct for Committee on Publication Ethics (COPE) and the ICMJE (PDF). Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript (for further details see: icmje.org/icmje-recommendations.pdf) (PDF).
Ethical considerations, compliance and protocol approval
Compliance with guidelines on human experimentation as well as protocol approval by a local Institutional Review Board should be stated and the approval number should be provided. Clinical trials should include the full protocol as a supplement. Studies involving human subjects that are exempt from approval by an Institutional Review Board should mention this in an Ethical Considerations Statement in the Methods section or in a separate section at the end of the article.
Kidney Cancer supports the appropriate and responsible use of animals as experimental subjects. The U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS Policy) and the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Guide) should guide all animal research. Compliance with these guidelines as well as protocol approval by the Institutional Animal Care and Use Committee must be stated in the cover letter and specified in the Methods section of the article or in a separate section at the end of the article. .
Kidney Cancer affirms that misconduct, in the form of fabrication, falsification, or plagiarism, jeopardizes the success of the entire scientific endeavor. However, the primary responsibility for considering and resolving allegations of scientific misconduct must be pursued within the individual academic communities and institutions where the scientific work is carried out. Every author of articles or abstracts submitted for publication assumes full responsibility, within the limits of their professional competence, for the accuracy of the report. In the case of multiple-authored papers, each author should have made a significant intellectual or practical contribution to the scientific work. Authors submit articles with the understanding that reports must not have been submitted elsewhere.
Questions raised about the conduct of experiments or their presentation will be evaluated preliminarily by the Editors-in-Chief and, if appropriate, in consultation with the Associate Editor handling the review of the manuscript. If deemed appropriate, the matter will be referred to the institution where the scientific work in question was performed. The Journal expects that the matter would be reviewed in accordance with institutional procedures for handling allegations of misconduct. At all stages, every effort should be made to ensure that the process is fair and just, both for those who are accused of misconduct and for those who have raised the issue of scientific misconduct.
In the event that a published article or abstract is to be retracted, a statement of retraction will be published Kidney Cancer.
